ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

intismeran autogene

Also written as “Intismeran autogene”, “mRNA-4157” and “Intismeran”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Melanoma · Non-Muscle Invasive Bladder Neoplasms · Carcinoma, Renal Cell · Carcinoma, Squamous Cell, led by 2 companies.

Drug pageIntismeran autogene: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 27, 202312 company-led studies, 11 open or runningCo-development: Moderna and Merck, Oct 2022Next primary completion: Apr 23, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck109 open or runningphase 3since Jun 27, 2023Jun 27, 2023Apr 23, 2027phase 2 · NCT06305767
Modernaits history only22 open or runningphase 2since Mar 29, 2019Oct 13, 2017Nov 21, 2027phase 1 · NCT03313778
  • Named in Merck’s own pipeline as intismeran autogene (V940), phase 3, as of Nov 2, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Merck only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Oct 12, 2022Merck develops it with ModernaCo-developmentWorldwide, costs and profits shared equally · announced · Merck
  2. Jun 27, 2023First study: phase 3 study in MelanomaFirst studyNCT05933577 · 1,089 enrolled · United States, Argentina, Australia and more
  3. Oct 5, 2023Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06077760 · 868 enrolled · United States, Argentina, Australia and more
  4. Feb 29, 2024Phase 3 study in Carcinoma, Squamous CellNCT06295809 · 46 enrolled · United States, Argentina, Australia and more
  5. Mar 5, 20242 phase 2 studiesNCT06305767, NCT06307431
  6. Aug 11, 2024Named intismeran autogeneINNProposed as its International Nonproprietary Name in WHO's List 131
  7. Sep 5, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06623422 · 680 planned · United States, Argentina, Australia and more
  8. Feb 4, 2025Phase 2 study in Urinary Bladder NeoplasmsNCT06833073 · 308 planned · United States, Argentina, Australia and more
  9. Apr 29, 2025Phase 2 study in MelanomaNCT06961006 · 160 enrolled · United States, Australia, Canada and more
  10. Oct 24, 2025Phase 2 study in Squamous Non-small Cell Lung CancerNCT07221474 · 180 planned · United States, Argentina, Australia and more
  11. Apr 1, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07513376 · 876 planned · United States, Australia, Brazil and more

Ahead

  1. Apr 23, 2027Primary completion: phase 2 study in Urinary Bladder NeoplasmsNCT06305767
  2. Jan 8, 2028Primary completion: phase 2 study in Carcinoma, Renal CellNCT06307431
  3. Jul 22, 2028Primary completion: phase 2 study in MelanomaNCT06961006
  4. Jul 2, 2029Primary completion: phase 2 study in Squamous Non-small Cell Lung CancerNCT07221474

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“An mRNA-based individualized, therapeutic personalized cancer vaccine (PCV) targeting thirty-four tumor-associated antigens (TAAs) that are specifically expressed by the patient's cancer cells and encapsulated in lipid nanoparticles, with potential immunostimulatory and antineoplastic activities.…”NCIt, read by Claude

Studies

All 10 Merck leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07513376Carcinoma, Non-Small-Cell Lung · United States, Australia, Brazil and more3RecruitingAug 22, 2034876
NCT07221474Squamous Non-small Cell Lung Cancer · United States, Argentina, Australia and more2RecruitingJul 2, 2029180
NCT06961006Melanoma · United States, Australia, Canada and more2Active, not recruitingJul 22, 2028160
NCT06833073Urinary Bladder Neoplasms · United States, Argentina, Australia and more2RecruitingSep 3, 2031308
NCT06623422Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingMay 16, 2033680
NCT06307431Carcinoma, Renal Cell · United States, Argentina, Australia and more2Active, not recruitingJan 8, 2028272
NCT06305767Urinary Bladder Neoplasms · United States, Australia, Canada and more2Active, not recruitingApr 23, 2027230
NCT06295809Carcinoma, Squamous Cell · United States, Argentina, Australia and more3TerminatedMar 5, 202646
NCT06077760Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3Active, not recruitingJun 25, 2030868
NCT05933577Melanoma · United States, Argentina, Australia and more3Active, not recruitingOct 26, 20291,089

How it is read

Names in the registry

  • “Intismeran autogene”, 8 entries
  • “mRNA-4157”, 2 entries
  • “Intismeran”, 1 entry
  • “Intismeran Autogene”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.